Equities Analysts Issue Forecasts for XENE FY2028 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Investment analysts at Wedbush dropped their FY2028 earnings estimates for shares of Xenon Pharmaceuticals in a report released on Friday, February 28th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will earn $1.22 per share for the year, down from their prior forecast of $1.42. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.05.

A number of other equities analysts also recently commented on the company. HC Wainwright restated a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday. Needham & Company LLC reissued a "buy" rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating and a $67.00 target price for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $57.38.

Xenon Pharmaceuticals Stock Down 3.3 %

Shares of XENE traded down $1.23 during midday trading on Monday, reaching $35.79. 745,690 shares of the stock were exchanged, compared to its average volume of 448,185. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -12.69 and a beta of 1.20. Xenon Pharmaceuticals has a 12-month low of $33.27 and a 12-month high of $47.80. The firm has a 50 day simple moving average of $39.27 and a 200-day simple moving average of $40.33.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the company's stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Ian Mortimer sold 16,315 shares of the business's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares in the company, valued at approximately $1,267,731. This represents a 34.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 57,492 shares of company stock worth $2,334,969 in the last 90 days. 5.52% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Loomis Sayles & Co. L P boosted its stake in shares of Xenon Pharmaceuticals by 7.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company's stock valued at $27,843,000 after purchasing an additional 46,964 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Xenon Pharmaceuticals by 57.1% in the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company's stock worth $32,480,000 after acquiring an additional 300,000 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Xenon Pharmaceuticals by 4.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 439,074 shares of the biopharmaceutical company's stock worth $17,287,000 after purchasing an additional 17,953 shares during the period. JPMorgan Chase & Co. lifted its stake in Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock valued at $38,456,000 after buying an additional 905,129 shares in the last quarter. Finally, Barclays PLC lifted its position in Xenon Pharmaceuticals by 1,275.5% in the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock valued at $590,000 after acquiring an additional 13,903 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.